Zhongnan Hospital
Clinical trials sponsored by Zhongnan Hospital, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Eyeliner may dry your eyes: new study investigates Results expected Sep 2026 (estimated)
- Minimally invasive eye surgery could ease a rare form of glaucoma Results expected Sep 2026 (estimated)
- New eye drainage procedure aims to lower pressure in advanced glaucoma Results expected Dec 2026 (estimated)
- Immunotherapy plus chemo shows promise in rectal cancer trial Results expected Jan 2027 (estimated)
- Kidney transplants: a smarter way to dose Anti-Infectives? Results expected Jan 2027 (estimated)
-
New drug cocktail aims to shrink liver tumors for surgery
Disease control Not yet recruitingThis phase II trial tests a chemotherapy regimen called FULIRI, combined with either bevacizumab or cetuximab, as a first treatment for colorectal cancer that has spread to the liver. The goal is to shrink the liver tumors enough so they can be surgically removed. The study will …
Phase 2 • Sponsor: Zhongnan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Promising drug cocktail targets Hard-to-Treat cervical cancer
Disease control Not yet recruitingThis phase II trial tests a combination of two drugs—Utidelone and Toripalimab—in people with recurrent or metastatic cervical cancer that has stopped responding to standard treatments. All 32 participants will receive the same treatment, and doctors will monitor tumor shrinkage …
Phase 2 • Sponsor: Zhongnan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New imaging agent could spot hidden cancers
Diagnosis Not yet recruitingThis study tests a new radioactive imaging agent called 68Ga-SFB6-ZN01, which is designed to attach to a protein found on many cancer cells. 98 adults with confirmed or suspected cancer will receive a single injection of the agent and then have a PET/CT scan. The goal is to see i…
Early phase 1 • Sponsor: Zhongnan Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 09:09 UTC
-
New Dual-Target PET probe aims to sharpen cancer detection
Diagnosis Not yet recruitingThis study will test a new imaging agent called 68Ga-B6FA-01, which targets two different markers on cancer cells and their surroundings. The goal is to see if this probe can improve PET/CT scans for diagnosing and staging solid tumors. About 100 adults with newly diagnosed or re…
Sponsor: Zhongnan Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 09:01 UTC
-
New head zaps aim to ease Parkinson's tremors without surgery
Symptom relief Not yet recruitingThis study tests a non-invasive device called Temporal Interference Stimulation (TIS) to see if it can improve movement in people with Parkinson's disease. The device uses electrical fields to stimulate deep brain areas without surgery. Twenty-four adults with mild to moderate Pa…
Sponsor: Zhongnan Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Can immune monitoring replace drug levels for kidney transplant dosing?
Knowledge-focused Not yet recruitingKidney transplant recipients take tacrolimus to prevent rejection, but standard drug-level monitoring cannot show whether the immune system is over- or under-suppressed. This observational study follows 50 adults for 12 months after a first kidney transplant, measuring immune mar…
Sponsor: Zhongnan Hospital • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Kidney transplants: a smarter way to dose Anti-Infectives?
Knowledge-focused Not yet recruitingThis study explores whether tracking rapid changes in kidney function right after a kidney transplant can help doctors choose the right dose of anti-infective drugs. Currently, dosing relies on static tests that may not reflect the fast shifts in kidney performance during the fir…
Sponsor: Zhongnan Hospital • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC